IQV Stock Recent News

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) will announce its third-quarter 2024 financial results before the market opens on Thursday, October 31, 2024. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time on that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at http://ir.iqvia.com. To listen to the event and view the presentatio.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced that Frost & Sullivan, a leading independent research and consulting firm, has awarded IQVIA with the 2024 Global Customer Value Leadership Award for excellence in the global artificial intelligence (AI) quality and regulatory solutions space for the healthcare industry. Frost &am.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

RBC Capital Markets initiated coverage on IQVIA Holdings Inc. IQV, noting the company's biggest differentiator is its data assets. The analyst says IQVIA is the largest global contract research organization.

PHILADELPHIA , Sept. 4, 2024 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today it has joined IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry, in its One Home for Sites™ initiative.

IQVIA (IQV) reported earnings 30 days ago. What's next for the stock?

IQVIA Holdings Inc. stock is up following Q2 earnings, following business upsides across its portfolio. Q2 earnings showed strong performance in TAS and R&DS divisions, with a record backlog and increased guidance for FY'24. Implied valuations are corroborated at a $260/share price objective, with potential further technical upside to $283/share if momentum sustains.

IQVIA (IQV) rides high on robust segmental performance, boosting the company's top line. However, elevated operating expenses and weak liquidity are a major concern.

Examine the evolution of IQVIA's (IQV) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.